Dilution corrected titres were reported for samples if results did not fall within the quantifiable range of the standard curve. The assay has been adapted, standardized and validated at Department of Gastrointestinal Sciences, Christian Medical
College, Vellore. The lower limit cut off value for the assay is 7 units/mL. Stool specimens obtained 3, 5 and 7 days after each dose of BRV-TV vaccine/RotaTeq/Placebo were tested for rotavirus VP6 antigen using a commercial enzyme immunoassay kit (Premier Rota clone Qualitative EIA, Meridian Bioscience Inc., Cincinnati, USA). Each positive sample was also tested to determine the rotaviral Autophagy Compound Library order G and P types using reverse transcription PCR . Healthy adult volunteers in Cohort 1 were kept under observation at the clinic for 30 min to
monitor for any immediate adverse events (Reactogenicity Events) after administration Pazopanib of the vaccine or placebo. Thereafter volunteers were given a thermometer and a Symptom Diary (SD) covering Days 0–10 for safety follow up. They were instructed to observe and record their axillary temperature twice daily as well as any Adverse Events (AEs) on the SD for 10 days after the dose of the BRV-TV vaccine/Placebo. Study volunteers were instructed to return to the clinic on Day 10 after administration of the BRV-TV vaccine/Placebo as an outpatient and whenever they had any symptoms. The diary card contained a list of solicited only events and blank spaces to capture any unsolicited events. All
healthy infants recruited in Cohort 2 were observed for 30 min post vaccination for immediate adverse events at the study site. Subsequently, the subject’s parents/guardians were given a thermometer, a Symptom Diary (SD) covering Days 0–6 and a second SD covering Days 7–27 for safety follow up following each of the three doses. They were instructed to observe and record their child’s axillary temperature twice daily as well as any AEs up to 7 days after each dose in the first SD, and from day 7 to day 27 in the second SD. Parents/guardians were instructed to bring the study infants to the study clinic on Day 7 and Day 28 after each administration of the BRV-TV vaccine/RotaTeq/Placebo as an outpatient and whenever any symptoms developed. The diary card contained list of solicited events and blank spaces to capture any unsolicited events. All the subjects in Cohort 2 were also evaluated for haematological and biochemical parameters before the first dose and 28 days after third dose of vaccine/placebo. An independent Data Safety Monitoring Board (DSMB) oversaw the trial and had access to all the safety information subsequent to each dose and the study randomization codes. The DSMB was empowered to recommend the stopping of the trial in the event of any safety concerns with the BRV-TV vaccine/RotaTeq/Placebo.